>
Organization
Ionis Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Ionis Pharmaceuticals, Inc.

... PR Newswire Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that Management will ...
... PR Newswire Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its Board of Directors announced today that, effective January ...
... Alnylam and Ionis are in a head-to-head battle for market share with their new treatments ...
... of metabolic complications in patients with generalized lipodystrophy. Key players such as Ionis Pharmaceuticals, Zydus Cadila and many others are involved in developing therapies for ...
... plans to advance BIIB067 to a pivotal clinical study * Biogen paid Ionis Pharmaceuticals a $35 million one-time upfront payment and may pay potential milestone ...
... antisense oligonucleotide designed to down-regulate SCN2A, which is being developed with Ionis Pharmaceuticals, Inc. (Ionis), the leader in RNA-targeted drug discovery and development. In preclinical ...
... (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that it will present the long-term analyses of the ...
... close collaboration with the SMA community, academia, researchers and our colleagues at Ionis, which has made a meaningful difference in this area of high unmet ...
... PR Newswire Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that data from ...
Subscribe now for full coverage on Ionis Pharmaceuticals, Inc.
Start My Free Trial